Table 2 |
||||||
| Number of CSF and serum samples analysed for each signalling protein in each group | ||||||
| Groups | IL-6 | VEGF | TGF-ß1 | |||
| n of samples | CSF | Serum | CSF | Serum | CSF | Serum |
| SRMA | 26 | 28 | 21 | 28 | 36 | 35 |
| SRMA R | 9 | 8 | 9 | 8 | 0 | 0 |
| SRMA Th | 41 | 44 | 41 | 45 | 0 | 0 |
| ME | 13 | 13 | 11 | 17 | 39 | 35 |
| CNS-Mix | 21 | 22 | 18 | 20 | 29 | 26 |
| Syst. Inflam. | 7 | 12 | 3 | 16 | 0 | 0 |
| IE | 22 | 16 | 14 | 14 | 0 | 0 |
| Healthy | 8 | 8 | 8 | 8 | 20 | 15 |
IL-6: interleukin-6; VEGF: vascular endothelial grow factor; TGF-β1: Transforming growth factor beta; CSF: cerebrospinal fluid; CNS: central nervous system; SRMA: steroid-responsive meningitis-arteritis; Syst Inflam: systemic inflammatory diseases; ME: other inflammatory CNS diseases; CNS-Mix: miscellaneous non-inflammatory CNS diseases; IE: idiopathic epilepsy.
Maiolini et al. BMC Veterinary Research 2013 9:23 doi:10.1186/1746-6148-9-23
